Katy Winckworth-Prejsnar named co-chair of Global Health Council Roundtable

Asia Society Policy Institute, Cure4Cancer call for expansion of U.S.-Australia cancer alliance

Asia Society Policy Institute’s Center for China Analysis and Cure4Cancer jointly published “Advancing Global Health Equity: Expanding the U.S.-Australia Cancer Alliance Toward an Asia-Pacific Collaborative Effort to Save Millions of Lives.”

December 06, 2024

Vol.50 No.45

Clinical Roundup

NCCN updates CML treatment guidelines following FDA approval of Scemblix for newly diagnosed patients

The National Comprehensive Cancer Network updated its chronic myeloid leukemia treatment guidelines, recommending Scemblix (asciminib) for the treatment of adults with newly diagnosed Ph+ CML-CP as a category 1-preferred.

November 22, 2024

Vol.50 No.44

Drugs & Targets

FDA issues draft guidance on conducting multiregional clinical trials in oncology

FDA issued a draft guidance for industry that, when finalized, will provide sponsors with recommendations for conducting multiregional clinical trials in support of applications for drugs intended to treat cancer.

September 20, 2024

Vol.50 No.35

Drugs & Targets

NCCN adds Lymphir to Clinical Practice Guidelines in Oncology

The National Comprehensive Cancer Network added Lymphir (denileukin diftitox-cxdl), a novel immunotherapy for the treatment of relapsed or refractory cutaneous T-cell lymphoma after at least one prior systemic therapy, to the NCCN Clinical Practice Guidelines in Oncology. Lymphir is included based on an NCCN Category 2A recommendation which indicates a uniform NCCN consensus that the drug is appropriate as an option for patients with CTCL.

September 06, 2024

Vol.50 No.33

Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.

July 19, 2024

Vol.50 No.29

By Jacquelyn Cobb

Health Equity White House

Cancer Moonshot contributes additional $100M to reduce cancer burden in Africa

Source: Livestream of White House Africa Cancer Care ForumThe White House Cancer Moonshot is committing an additional $100 million to programs focused on reducing cancer burden in African countries.

July 19, 2024

Vol.50 No.29

By McKenzie Prillaman

Katy Winckworth-Prejsnar named co-chair of Global Health Council Roundtable

YOU MAY BE INTERESTED IN

Asia Society Policy Institute, Cure4Cancer call for expansion of U.S.-Australia cancer alliance

NCCN updates CML treatment guidelines following FDA approval of Scemblix for newly diagnosed patients

FDA issues draft guidance on conducting multiregional clinical trials in oncology

NCCN adds Lymphir to Clinical Practice Guidelines in Oncology

Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

Cancer Moonshot contributes additional $100M to reduce cancer burden in Africa

Renew today!

Subscriber content

Never miss an issue!

Login

Katy Winckworth-Prejsnar named co-chair of Global Health Council Roundtable

YOU MAY BE INTERESTED IN

Asia Society Policy Institute, Cure4Cancer call for expansion of U.S.-Australia cancer alliance

NCCN updates CML treatment guidelines following FDA approval of Scemblix for newly diagnosed patients

FDA issues draft guidance on conducting multiregional clinical trials in oncology

NCCN adds Lymphir to Clinical Practice Guidelines in Oncology

Platinum drugs are off the shortage list, but the underlying problem is unsolvedFDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

Cancer Moonshot contributes additional $100M to reduce cancer burden in Africa

Never miss an issue!

Login

Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”